• Early clinical stage drug
   
• Active in vivo: in human colon, breast and prostate cancer animal models, with reduced toxicity
   
• Status: IND FDA approved
   
• IP: Patent protection through 2019
   
• Development Plan: Start Phase 1 trial Q4 2012
   
• Relevant Biomarker: TS
   
• Estimated Market Potential: >$1B

Technology was initially developed by Lipitek International/Genencor and licensed exclusively to OncoVista.

Cancer causes significant changes in the cell membrane.

L- Nucleosides enter cells selectively, specifically targeting cancerous cells without affecting healthy cells.

Conjugation of L-nucleosides to other anti-cancer compounds allows selective targeting of anti-cancer compounds to the tumor, reducing systemic toxicity associated with typical chemotherapeutic agents.

Our lead compound (OVI-117) has completed GLP animal drug safety studies and the IND is being drafted.